Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • TA406
  • Published: 
Download guidance (PDF)

3 Evidence

The appraisal committee considered evidence submitted by Pfizer and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.